Search results for "digestive system"

showing 10 items of 1747 documents

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Novel cytokine-targeted therapies and intestinal inflammation

2009

Several cytokines have been identified as critical mediators of chronic inflammation in inflammatory bowel disease (IBD) and biological therapies that target these molecules have been developed during recent years. Thereby, anti-TNF agents have noticeably improved the treatment of patients with IBD in comparison to conventional therapy. Furthermore, initial clinical trials showed promising results with anti-IL-6 and anti-IL-12/IL-23 agents. In addition to these well-known mediators of IBD, various novel cytokines have been described as critical during the pathogenesis of IBD in recent experimental studies and therapeutic targeting of these cytokines could provide new strategies for human di…

medicine.medical_treatmentInflammationTherapeutic targetingInflammatory bowel diseaseAntibodiesPathogenesisDrug Delivery SystemsIntestinal inflammationDrug DiscoverymedicineAnimalsHumansIntestinal MucosaPharmacologyBiological therapiesbusiness.industryModels ImmunologicalColitisInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesIntestinesClinical trialDisease Models AnimalCytokineImmunologyCytokinesmedicine.symptombusinessCurrent Opinion in Pharmacology
researchProduct

Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms

2019

Currently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that cannabidiol (CBD) could be a promising treatment for substance use disorders. In the present work, the authors describe the scarce preclinical and human research about the actions of CBD on the effects of stimulant drugs, mainly cocaine and methamphetamine (METH). Additionally, the possible mechanisms underlying the therapeutic potential of CBD on stimulant use disorders are reviewed. CBD has reversed toxicity and seizures induced by cocaine, behavioural sensitization induced by amphetamines, motivation to self-administer cocaine and METH, context- …

medicine.medical_treatmentPharmaceutical ScienceCravingReviewPharmacologyAnalytical ChemistryHealth Risk Behaviorschemistry.chemical_compoundcannabidiol0302 clinical medicineDrug DiscoveryMedicineratrewardmedia_commonResilience PsychologicalMethamphetamineconditioned place preferenceSubstance Withdrawal SyndromeObservational Studies as TopicChemistry (miscellaneous)Molecular Medicineaddictionmedicine.symptomSelf-administrationself-administrationmedicine.drugmicemedia_common.quotation_subjectAmphetamine-Related DisorderscocaineContext (language use)lcsh:QD241-441Cocaine-Related Disorders03 medical and health scienceslcsh:Organic chemistryAnimalsHumansPhysical and Theoretical Chemistrymethamphetaminebusiness.industryAddictionOrganic ChemistryMeth-Conditioned place preferencedigestive system diseasesreinstatement030227 psychiatryStimulantchemistrybusiness030217 neurology & neurosurgeryMolecules
researchProduct

Perfluoroalkylated amphiphilic MUC1 glycopeptide antigens as tools for cancer immunotherapy.

2010

The synthesis of perfluoroalkylated glycopeptide antigens and their specific binding to anti-MUC1 mouse antibodies is reported.

medicine.medical_treatmentdigestive systemCatalysisAntibodiesAntigen-Antibody ReactionsMiceAntigenCancer immunotherapyNeoplasmsAmphiphileMaterials ChemistrymedicineAnimalsAntigensskin and connective tissue diseasesneoplasmsMUC1Mice Inbred BALB CBinding SitesbiologyMolecular StructureChemistryMucin-1Metals and AlloysGlycopeptidesGeneral Chemistrybiological factorsdigestive system diseasesGlycopeptideSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsBiochemistryCeramics and Compositesbiology.proteinImmunotherapyAntibodyChemical communications (Cambridge, England)
researchProduct

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guideline…

2010

Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory…

methods Tumor Necrosis Factor-alphaAnti-Inflammatory AgentsUlcerativeDiseaseGUIDELINESHumanized Antibodieetiology Pregnancy Pregnancy ComplicationGastroenterologyInflammatory bowel diseaseetiology Opportunistic InfectionCrohn DiseasePregnancyNeoplasmsMonoclonaldrug therapy Remission Inductionantagonists /&/ inhibitorsSettore MED/12 - GastroenterologiaRemission InductionGastroenterologyAntibodies MonoclonalUlcerative colitisAnti-Inflammatory AgentItalyadverse effects/therapeutic use Intestinal FistulaTumor necrosis factor alphaFemaleImmunosuppressive Agentsmedicine.drugbiological drugsmedicine.medical_specialtyIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedAutoimmune Diseasesadverse effects/therapeutic use Autoimmune DiseaseInternal medicinemedicineAdalimumabIntestinal FistulaHumansColitisdiagnosis/drug therapy/surgery Italy Neoplasmadverse effects/therapeutic use AntibodieHepatologydrug therapy Female Humans Immunosuppressive Agentbusiness.industryTumor Necrosis Factor-alphaAdalimumabCancermedicine.diseaseInfliximabInfliximabdigestive system diseasesdrug therapy Crohn Diseaseetiology ColitiPregnancy ComplicationsColitis Ulcerativebusiness
researchProduct

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

2020

Introduction We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). Methods ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Results Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Discussion Once AIH has been ruled out, the long-term outcomes and survival are un…

musculoskeletal diseasesMalemedicine.medical_specialtyAntibodies Antinuclear; Biopsy; England; Female; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prospective Studies; Survival AnalysisAnti-nuclear antibodyBiopsySettore MED/12 - GASTROENTEROLOGIAAntibodies Antinuclear Biopsy EnglandFemale Humans Italy Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease Prevalence Prospective StudiesSurvival AnalysisAutoimmune hepatitisMalignancyGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineimmune system diseasesNon-alcoholic Fatty Liver DiseaseInternal medicineAntinuclearBiopsyNonalcoholic fatty liver diseasemedicineCarcinomaPrevalenceHumansLongitudinal StudiesProspective Studiesskin and connective tissue diseasesProspective cohort studySurvival analysisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseases3. Good healthstomatognathic diseasesn/aEnglandItaly030220 oncology & carcinogenesisAntibodies Antinuclear030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Arthralgia as an early extraintestinal symptom of Whipple's disease. Report of five cases.

1997

Five patients with Whipple's disease all suffered from arthralgia for a long time (15 years in one case) before developing gastrointestinal or other symptoms. In all patients, arthralgia was seronegative, and there was no evidence of joint destruction. Arthralgias were symmetric and migrating. Whipple's disease is part of the differential diagnosis of enteropathic arthralgia. Thereby, the polymerase chain reaction can be a helpful tool to prove Whipple's disease in difficult differential diagnosis.

musculoskeletal diseasesMalemedicine.medical_specialtyBiopsyDiagnostico diferencialDiseasePolymerase Chain ReactionIntestinal malabsorptionDiagnosis DifferentialBiopsymedicineHumansWhipple's diseaseskin and connective tissue diseasesmedicine.diagnostic_testJoint destructionBacteriabusiness.industryWhipple DiseaseGastroenterologyvirus diseasesMiddle Agedmedicine.diseaseDermatologyArthralgiadigestive system diseasesSurgerybody regionsDifferential diagnosisbusinessWhipple DiseaseJournal of clinical gastroenterology
researchProduct

Patología articular en la enfermedad inflamatoria intestinal

2005

The joint disorders taxonomically included in the group of seronegative spondyloarthropathies under the generic name of enteropathic arthropathy represent the most frequent extra-intestinal manifestation of inflammatory bowel disease (IBD), affecting 33% of patients. Their frequency is similar to that of ulcerative colitis and Crohn's disease. Enteropathic arthropathy consists of two main joint alterations, peripheral and axial arthritis, as well as a variable group of other peri-articular disorders. Type 1, or pauciarticular, peripheral arthritis generally coincides with IBD exacerbations, while type 2, or polyarticular, peripheral arthritis follows an independent course from IBD. Axial in…

musculoskeletal diseasesmedicine.medical_specialtyAnkylosing spondylitisHepatologyEnteropathic arthropathybusiness.industryGastroenterologySacroiliitisArthritismedicine.diseaseGastroenterologyInflammatory bowel diseaseAsymptomaticUlcerative colitisdigestive system diseasesInfliximabInternal medicinemedicinemedicine.symptombusinessmedicine.drugGastroenterología y Hepatología
researchProduct

Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report …

2019

Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease characterised by fever and arthritis. We describe the case of a 14-year-old girl hospitalised with fever associated with rash, myalgia, arthralgia and polyarticular involvement. Examinations revealed increased levels of C-reactive protein, erythrocyte sedimentation rate, ferritin, triglycerides, leukocytes, neutrophils, lactate dehydrogenase, fibrinogen, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT). Bone marrow biopsy showed polyclonal leukocyte activation. A genetic study revealed a heterozygous mutation of the MEFV gene, c.442G>C (E148Q), which is typical of…

myalgiaAbdominal painmedicine.medical_specialtyTime FactorsAdolescentCanakinumabFamilial Mediterranean feverArthritisCase Report030204 cardiovascular system & hematologyAntibodies Monoclonal Humanized030226 pharmacology & pharmacyGastroenterology03 medical and health sciences0302 clinical medicineautoinflammatory diseaseInternal medicinemedicineHumansPharmacology (medical)medicine.diagnostic_testbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineExanthemamedicine.diseaseMEFVRashdigestive system diseasesArthritis JuvenileCanakinumabTreatment OutcomeErythrocyte sedimentation rateSystemic juvenile idiopathic arthritiFemalemedicine.symptombusinessmedicine.drug
researchProduct

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

2018

There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA…

neoplasmsdigestive system diseases
researchProduct